King & Wood Mallesons (“KWM” or “the Firm”) has advised Ysios Capital on the structuring and close of its third fund, Ysios BioFund III (“YBF III” or the “Fund”), which has reached a final size of €216 million. The Fund will invest broadly across multiple therapeutic areas and modalities, targeting seed/early stage and development-stage companies at the forefront of the future of medicine. The total investment size per company will typically be of up to €20 million.
Ysios Biofund III has been supported by the European Investment Fund with nearly €60 million. Other investors are insurance companies, family offices, pension funds, local agencies, business corporations, as well as the main partners of the private equity firm.
Isabel Rodríguez, Partner and Head of the Funds team at KWM - Spain, has been in charge of the coordination of the advice to Ysios Capital. Other key members of the team have been Partner Ildefonso Alier and Associate María Mata.
KWM had previously advised Ysios on the structuring of its funds Ysios BioFund I and Ysios BioFund II.